Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Artiva Biotherapeutics (Nasdaq: ARTV) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 1:10 p.m. EST in Boston.
Artiva management will meet registered investors and the audio webcast plus archived recording will be available on the company investor website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – ARTV
On the day this news was published, ARTV gained 0.20%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $273K to the company's valuation, bringing the market cap to $137M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key peers in biotechnology like ACET, ALXO, INKT, CELU, and VANI all show positive price changes (e.g., ACET 6.98), but only one momentum-scanner peer (PMVP, up 6.6%) is flagged, and scanner data marks this as not a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | CFO appointment | Positive | +4.6% | New CFO hire with RSU grant and experience to support upcoming milestones. |
| Feb 19 | Board appointment | Positive | +3.4% | Appointment of experienced biopharma executive to the board of directors. |
| Jan 21 | Scientific presentations | Positive | +2.8% | Announcement of cost-effectiveness and durability data presentations for AlloNK. |
| Jan 08 | External leadership news | Positive | -0.4% | NanoSyrinx CEO appointment associated with ARTV but followed by slight share decline. |
| Nov 12 | Clinical data update | Positive | +10.9% | Positive initial safety and translational data for AlloNK in autoimmune disease. |
Recent Artiva news, especially management and clinical updates, has usually seen positive price alignment, with only one divergence in the last five events.
Over recent months, Artiva reported a series of developments, including positive autoimmune safety data on Nov 12, 2025 that saw a 10.86% gain, and scientific presentations announced on Jan 21, 2026 with a 2.81% rise. Management changes on Feb 19 and Feb 24, 2026 were also followed by gains of 3.37% and 4.58%, respectively. One external NanoSyrinx leadership headline on Jan 8, 2026 coincided with a modest -0.43% move. Today’s conference participation fits into a pattern of regular communication with incremental, generally well-received updates.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration dated 2025-08-06, expiring 2028-08-06. It is marked as not yet effective and shows 0 recorded usages in the provided context, indicating no documented takedowns so far in this dataset.
Market Pulse Summary
This announcement highlights Artiva’s upcoming fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 1:10 p.m. EST, with a webcast replay available for 90 days. It adds investor visibility but no new clinical or financial data. In context of prior positive clinical and management updates, investors may watch future disclosures, SEC filings, and how management uses its existing Form S-3 shelf when assessing longer-term implications.
AI-generated analysis. Not financial advice.
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.
Members of the Artiva management team will also be available to participate in meetings with investors who are registered to attend the conference.
To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
FAQ
When will Artiva (ARTV) present at the TD Cowen 46th Annual Health Care Conference?
How can investors access the Artiva (ARTV) fireside chat webcast from March 4, 2026?
Will Artiva (ARTV) management be available for one-on-one meetings at TD Cowen on March 4, 2026?
How long will the Artiva (ARTV) conference webcast be available after March 4, 2026?
Where is the TD Cowen 46th Annual Health Care Conference where Artiva (ARTV) will appear?
